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Abstract
Background: Yersinia pestis, the causative agent of plague, is a pathogen with a tremendous ability
to cause harm and panic in populations. Due to the severity of plague and its potential for use as a
bioweapon, better preventatives and therapeutics for plague are desirable. Subunit vaccines
directed against the F1 capsular antigen and the V antigen (also known as LcrV) of Y. pestis are under
development. However, these new vaccine formulations have some possible limitations. The F1
antigen is not required for full virulence of Y. pestis and LcrV has a demonstrated
immunosuppressive effect. These limitations could damper the ability of F1/LcrV based vaccines to
protect against F1-minus Y. pestis strains and could lead to a high rate of undesired side effects in
vaccinated populations. For these reasons, the use of other antigens in a plague vaccine formulation
may be advantageous.
Results: Desired features in vaccine candidates would be antigens that are conserved, essential for
virulence and accessible to circulating antibody. Several of the proteins required for the
construction or function of the type III secretion system (TTSS) complex could be ideal contenders
to meet the desired features of a vaccine candidate. Accordingly, the TTSS needle complex protein,
YscF, was selected to investigate its potential as a protective antigen. In this study we describe the
overexpression, purification and use of YscF as a protective antigen. YscF immunization triggers a
robust antibody response to YscF and that antibody response is able to afford significant protection
to immunized mice following challenge with Y. pestis. Additionally, evidence is presented that
suggests antibody to YscF is likely not protective by blocking the activity of the TTSS.
Conclusion: In this study we investigated YscF, a surface-expressed protein of the Yersinia pestis
type III secretion complex, as a protective antigen against experimental plague infection.
Immunization of mice with YscF resulted in a high anti-YscF titer and provided protection against
i.v. challenge with Y. pestis. This is the first report to our knowledge utilizing a conserved protein
from the type III secretion complex of a gram-negative pathogen as a candidate for vaccine
development.
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Yersinia pestis, the causative agent of plague, causes rapidly
progressing disease in humans with a high mortality rate,
especially in the pneumonic form of the disease. Due to
the severe nature of plague, its ability for aerosol transmis-
sion, and the potential for human to human transmission
plague is considered to be a disease of high concern as an
agent of biological warfare or biological terrorism [1]. For
this reason, an improved vaccine for plague is desirable.
Current efforts for vaccine development have focused on
two proteins: LcrV (also known as the V antigen) and the
capsular F1 antigen [2]. The best results to date have been
obtained by using a combination of recombinant LcrV
and F1 subunits [3] separately or as a fusion protein [4,5].
These subunit vaccines demonstrate very good protection
against both pneumonic and systemic forms of plague [2]
in mouse models. One of the potential limitations of
these subunit vaccines is that F1 is not required for full vir-
ulence of Y. pestis, as F1-negative strains have the same
LD50 value as F1-positive strains [6-9]. A second limitation
that could result in undesired side-effects in immunized
individuals is the demonstrated immunosuppressive
effect of LcrV [10-13]. Additionally, serologic diversity of
LcrV has been reported, in Yersinia species other than Y.
pestis, that could theoretically limit the usefulness of an
LcrV based vaccine. While the recombinant subunit vac-
cines are very effective in experimental animals and offer
protection against F1 minus strains of Y. pestis [2], the
inclusion of other antigens with the LcrV/F1 subunit vac-
cine candidates could improve the ability of the resulting
vaccine to offer protection against multiple Y. pestis
strains, or the new antigens could be developed as sepa-
rate vaccine candidates.
The type III secretion apparatus encoded on the low-cal-
cium response (LCR) virulence plasmid, pCD1 in strain
KIM [14], of Y. pestis is a conserved virulence mechanism
that is absolutely required for virulence of Y. pestis [15].
YscF is a surface localized protein that is required both to
secrete Yops and to translocate toxins into eukaryotic cells
[16-19]. One report speculates that YscF polymerization is
required for a YscF needle to puncture eukaryotic cell
membranes [18]. Other researchers suggest that YscF and
its homologs function to provide a base that a translocon
complex is built upon, or that YscF builds a conduit from
the bacterium to the eukaryotic membrane [20]. This sug-
gestion seems more likely given that other proteins such
as YopB, YopD, and LcrV are also required for transloca-
tion into eukaryotic cells [21-28]. Additionally, YscF nee-
dle producing Y. enterocolitica deficient in production of
the translocators (LcrV, YopB, and YopD) do not translo-
cate Yops into macrophages, demonstrating that the YscF-
needle is not sufficient for translocation [19].
Most currently described pathogenesis-related type III
secretion systems possess homologs to YscF. In patho-
genic Salmonella and Shigella, the YscF homologs (PrgI and
MxiH, respectively) have been demonstrated to form a
needle structure that protrudes from the surface of bacte-
rial cells [29-31]. The best-characterized homolog of YscF
is EscF of enteropathogenic E. coli (EPEC). EscF is required
for "attaching and effacing" (A/E) lesion formation on the
intestinal mucosa and for type III secretion of effector pro-
teins [32-34]. EscF is thought to be a structural compo-
nent of the needle complex on the bacterial surface as it
binds EspA, the major component of a filamentous sur-
face organelle, and is required for formation of the EspA
filaments. [32-34] However, this surface localization has
never been visualized directly, as the only EscF antiserum
generated was unable to recognize the native protein [33].
Based on the fact that YscF is thought to be a surface-
expressed protein in Y. pestis and is required for virulence,
we sought to determine if YscF could serve as a protective
antigen against experimental plague infection. Immuniza-
tion of mice with His-tagged YscF resulted in a high anti-
YscF titer and significant protection against i.v. challenge
with Y. pestis. The findings of this study suggest that YscF
may be a potential plague vaccine candidate that could be
used in conjunction with other plague antigens, or possi-
bly alone if its efficacy can be improved by alternative
delivery methods.
Results and discussion
Expression and purification of HT-YscF
To facilitate the purification of YscF, yscF was cloned into
the overexpression plasmid pET24b (Novagen) to yield a
hexahistidine-tag on the C-terminus of YscF (HT-YscF). E.
coli BL21(DE3) harboring the HT-YscF expression plas-
mid, pJM119, was grown in one liter of LB broth [35] con-
taining kanamycin at 37°C. Expression of HT-YscF was
induced after 2 h of growth with 0.3 mM IPTG and then
incubated until the A550 reached ~1.0. Cells were har-
vested by centrifugation and disintegrated by passage
through a French pressure cell at 20,000 lb/in2. Subse-
quent to disintegration, the extracts were clarified by cen-
trifugation at 3,200 × g for 20 min at 4°C. Affinity
purification of HT-YscF was performed using Talon resin
(BD Clontech) using standard methods. Purity of the
recovered protein (> 95 %) was estimated by SDS-PAGE
on a 15% (wt/vol) gel followed by staining with a
Coomassie blue stain. The purified HT-YscF ran as multi-
ple bands on the gel, regardless of the presence or absence
of a reducing agent, such as dithiothreitol (data not
shown). A band that corresponded to the predicted size of
HT-YscF was the dominant species and other larger bands
could also be visualized (Figure 1A). Based on the sizes of
these bands, it is likely that they represent dimers and
other multimers of YscF. The presence of YscF multimersPage 2 of 10
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form multimeric structures [29,36]. Support for the con-
tention that the larger bands are multimers of YscF is seen
in Fig. 1B. Purified recombinant HT-YscF was immunob-
lotted with a Penta-His specific antibody (Qiagen). The
results seen in Figure 1 show that the larger bands seen in
panel A are also recognized by the penta-His antibody
(Fig. 1B) demonstrating that the larger bands are likely
recombinant proteins containing a poly-histidine tag and,
therefore, contain YscF. Additionally, the purified HT-
YscF was immunoblotted and probed with serum from
immunized mice (Fig. 1C) to demonstrate that the immu-
nized mice mounted an immune response against the
purified HT-YscF. The larger bands seen in the Coomassie
stain and visualized on the immunoblots (with both anti-
Penta-His antibody and post-immune sera) could also be
contaminating E. coli proteins, that cross-react to the
penta-His antibody, this possibility cannot be currently
discounted. The presence of the higher molecular weight
proteins, if they are not YscF multilmers and they are from
E. coli, likely had little influence on this study as immuni-
zation with HT-YscF induced a specific antibody response
to native YscF produced by Y. pestis (discussed below).
Specificity of the antibody response to YscF
To confirm that the recombinant HT-YscF antibody
response generated in immunized mice was directed
against YscF from Y. pestis, Y. pestis protein extracts from
the parental strain KIM8.3002 (pgm-, pla-) and extracts
from a isogenic yscF deletion strain (kindly provided by G.
Plano, University of Miami, Miami, Fl.) were immunob-
lotted and probed with pooled antiserum from HT-YscF
immunized mice (Figure 2). The results in Figure 2 dem-
onstrate that the pooled mouse antiserum specifically rec-
ognizes YscF produced by Y. pestis. As seen in Figure 2,
YscF is visualized on the immunoblot as a highly reactive
Purified HT-YscF was run on SDS-PAGE gels (12.5% for Panels A and B, 15% Panel C) to analyze purity of the recovered proteinFigure 1
Purified HT-YscF was run on SDS-PAGE gels (12.5% for Panels A and B, 15% Panel C) to analyze purity of the recovered pro-
tein. Panel A, separated proteins were stained with GelCode Blue stain (Pierce Chemical). Panel B, purified HT-YscF was 
immunoblotted to PVDF and probed with antibody specific for penta-histidine to identify which bands contained the His-tag. 
Panel C, purified HT-YscF was immunoblotted to PVDF and probed with post-immune serum from immunized mice.Page 3 of 10
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only seen only in strains containing the yscF gene (Figue
2, lanes 1–4). Importantly, no bands are seen in lanes 5
and 6 that contain proteins derived from the yscF deletion
strain. In lanes 1 and 2, calcium regulation of the YscF
band is seen as expected for the LCR-regulated yscF gene.
Transcomplementaion of the ∆yscF strain with pBAD-YscF
(G. Plano, University of Miami) restored YscF reactivity to
the HT-YscF serum in the ∆yscF strain (Figure 2, lanes 3
and 4). Demonstrating that the lack of YscF reactivity in
the ∆yscF strain was due to the deletion of yscF. The higher
molecular weight bands seen in the whole cell fraction
(Figure 2, lanes 1–6) represent cross-reactive Y. pestis
bands not specific to YscF, as they are present in the ∆yscF
samples. The same cross-reactive bands are also present in
whole cell samples probed with pre-immune serum (data
not shown) suggesting that the reactivity seen is not
induced by immunization with HT-YscF. The higher
molecular weight band seen in the culture supernatant
fractions could represent a multimer of YscF (possibly a
trimer) or YscF in complex with another secreted protein.
This higher molecular weight species is likely related to
YscF as a similar band is not seen with pre-immune sera
(data not shown) or in the ∆yscF strain (Figure 2). These
results demonstrate that mice immunized with recom-
binant HT-YscF produce antibodies that specifically recog-
nize YscF produced by Y. pestis.
Derivatives of Yersinia pestis KIM8-3002 (KIM5 pPCP1-minus, Smr) were grown in a chemically defined medium at 26°C for 2 h in the presence (la es 1, 3, and 5) or absence of calciu  (lanes 2, 4, and 6)Figure 2
Derivatives of Yersinia pestis KIM8-3002 (KIM5 pPCP1-minus, Smr) were grown in a chemically defined medium at 26°C for 2 h 
in the presence (lanes 1, 3, and 5) or absence of calcium (lanes 2, 4, and 6). Lanes 1 and 2 contain Y. pestis KIM8-3002. Lanes 3 
and 4 contain Y. pestis KIM8-3002 ∆yscF expressing YscF from pBAD18-YscF. Lanes 5 and 6 contain Y. pestis KIM8-3002 ∆yscF 
gene. After the 2 h growth, the culture was shifted to 37°C to induce expression of the Ysc type III secretion system and the 
Low Calcium Response. Following 4 h of growth at 37°C cultures, were centrifuged to obtain whole cell fractions and cell-free 
culture supernatant fractions. Total proteins from each fraction were precipitated with 10% trichloro acetic acid. Dried pro-
teins were resuspended in SDS-PAGE sample buffer and electrophoresed in a 15% SDS-PAGE gel. Proteins were then trans-
ferred to a PVDF membrane and immuno-blotted with pooled mouse serum used at a 1:20,000 dilution. Mouse serum was 
obtained by bleeding mice subsequent to immunization with HT-YscF, serum from several mice was pooled to control for ani-
mal specific variation. The position and sizes for the molecular weight markers are indicated and the position of YscF is shown.
Table 1: IgG response to HT-YscF vaccination and LD50 
determination.
Immunogen anti-YscF GMT* LD50 Fold increase in survival
PBS < 1:400 159 -
HT-YscF 1:40,000 21,344 134
*Geometric mean titer for total IgG, determined from 22 HT-YscF 
immunized mice.Page 4 of 10
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challenge with Y. pestis KIM5
To examine the ability of HT-YscF to protect mice from Y.
pestis infection outbred mice were immunized intra peri-
toneally with purified HT-YscF using complete Freund's
adjuvant (CFA) for primary immunization and incom-
plete Freund's adjuvant (IFA) for booster immunizations
or with a phosphate-buffered saline (PBS, [37]) control in
CFA or IFA to control for adjuvant effects. For these stud-
ies, 6-to 8-week-old female Swiss-Webster mice were
immunized i.p. with 40 µg/mouse HT-YscF in PBS or PBS
(control mice) alone emulsified 1:1 with CFA.
Experimental mice were boosted with 40 µg/mouse HT-
YscF in IFA after two weeks and with 20 µg/mouse HT-
YscF in IFA at 4 weeks post-immunization. Negative con-
trol mice were boosted with PBS emulsified with IFA
according to the same schedule. Two weeks following the
final booster immunization, sera were collected from the
HT-YscF-immunized and the PBS-immunized mice to
assay for HT-YscF reactivity. Sera from 22 mice from the
HT-YscF-immunized and the PBS-immunized groups
were tested for total IgG reactivity. HT-YscF immunized
mice had a geometric mean titer of 1:40,000 for IgG spe-
cific to HT-YscF while PBS-immunized mice had HT-YscF
titers less than the lowest dilution 1:800 (Table 1). After
establishing that the HT-YscF immunized mice had devel-
oped a strong antibody response to HT-YscF, the mice
were challenged with Y. pestis. Two weeks after the final
immunization, groups of 10 mice were challenged intra
venously via the retro-orbital sinus with 101 to 106 CFU Y.
pestis KIM5 (pgm-) in PBS (grown at 26°C). The mice were
observed for 19 days after challenge, and the average
doses required to kill 50% of the mice (LD50) for the treat-
ment groups were calculated using the extrapolation
method of Reed and Muench [38]. Mice that were immu-
nized with HT-YscF demonstrated a 134-fold increase in
the calculated LD50 value as compared to PBS-immunized
mice (Table 1). These results demonstrate that immuniza-
tion of mice with HT-YscF was able to provide a degree of
protection to the immunized mice from a subsequent
challenge with Y. pestis (Table 1). While the protection
provided by HT-YscF is not of the same magnitude as that
seen with the protective antigens F1 or LcrV, the increased
LD50 value clearly shows that immunization with YscF
affords a significant level of protection. Thus, HT-YscF
becomes the only other reported antigen apart from LcrV
or F1 to induce a significant protection in F1-positive Y.
pestis. Immunization with YopD has been demonstrated
to provide significant protection against a F1-minus
mutant of Y. pestis [39]. The protection generated by HT-
YscF suggests that YscF could be potentially developed as
a novel subunit vaccine for Y. pestis or could serve as an
additional antigen in a multivalent Y. pestis vaccine com-
prised of YscF, F1, and LcrV for example.
Characterization of the antibody response to HT-YscF
Mice immunized with HT-YscF demonstrated a strong
antibody response to YscF and provided protection to the
vaccinated mice from lethal Y. pestis challenge. Due to the
strong antibody response, isotyping analysis was per-
formed to determine the predominant isotypes of anti-
bodies produced by mice in response to vaccination with
HT-YscF in CFA/IFA. Anti-YscF antibody titers were deter-
mined two weeks following the last immunization, prior
to challenge. The YscF-specific antibody titers of PBS-
immunized mice were below the ELISA assay baseline of
1:800 (Table 1), as was the pre-immune serum (data not
shown). However, the HT-YscF immunized mice reached
a GMT (geometric mean titer) of 1:40,000 (Table 1) for
total IgG. Isotyping analysis was performed on the pooled
sera obtained from the 22 mice selected for total the IgG
analysis reported in Table 1. Pooled sera were used to
minimize the animal to animal variation expected from
using outbred mice. The isotyping analysis demonstrated
no significant IgA or IgM production (Table 2) and a very
high IgG titer (Table 2) as expected from the data in Table
1. Among the IgG subclasses IgG2b appeared to have the
highest levels (Table 2), although IgG1 and IgG2a levels
were also very high (Table 2). IgG3 levels were the lowest
(Table 2). Generally, immunization with CFA tends to
drive a strong Th1 response. Immunization with HT-YscF
in CFA induced a strong Th1 response, evident by the high
IgG2a response. However, a strong Th2 response is also
present as seen by the high IgG1 and IgG2b levels. Immu-
nization with HT-YscF induced a strong IgG1 response in
mice and interestingly, Titball et al. have shown that high
IgG1 titers to a F1/LcrV recombinant subunit vaccine cor-
related very well with protection against pneumonic
plague in mice [40]. This suggests that YscF, which also
induces a strong IgG1 response, could possibly afford
some protection against pneumonic challenge as well as
against systemic challenge.
Table 2: Antibody isotype titers from mice* immunized with 
HT-YscF.
Antibody isotype Titer
Total Ig 1:100,000
IgM < 1:800
IgG1 1:100,000
IgG2a 1:100,000
IgG2b > 1:100,000
IgG3 1:20,000
IgA < 1:800
*Sera from 22 mice were pooled for this analysis.Page 5 of 10
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To examine one possible method that anti-YscF could be
functioning to provide protection in immunized animals
the ability to translocate Yops in the presence of anti-YscF
antiserum was examined. Antibody to the surface-local-
ized LcrV has been shown to block the ability of the TTSS
in Y. pestis to translocate Yops into cultured macrophages
[41,42] but anti-LcrV was unable to block translocation
into HeLa cells [21].
However, anti-LcrV was able to block Yops translocation
by Y. pseduotuberculosis into HeLa cells [26]. Since YscF is
also surface-localized the ability of anti-HT-YscF to block
Yop translocation into HeLa cells was tested. Day et al
have described an elegant methodology to follow the
translocation of Yop effector by fusing them to a Elk
reporter [43]. Elk, a eukaryotic transcriptional activator,
becomes phosphorylated only after entering the nucleus,
providing a reporter for translocation into eukaryotic cells
[43,44]. This methodology has the advantage of not
requiring cell fractionation and protease protection assays
to establish the intracellular localization of translocated
proteins. To test the ability of anti-YscF to block transloca-
tion Y. pestis KIM8-3002 was transformed with plasmid
pYopE129-Elk [43]. HeLa cells were infected at an MOI of
10 and infection was allowed to progress for 4 h. After the
4 h incubation infected HeLa cells were harvested and
immunoblotted to analyze YopE, Elk and PO4-Elk pro-
duction. Y. pestis KIM8-3002 (wt; [24]) and an isogenic
translocation defective strain containing a yopD deletion
(KIM8-3002.2, ∆yopD; [45]) both containing pYopE129-
Elk were used as positive and negative translocation con-
trols, respectively. Immunoblots of HeLa cells infected
with the wt and the ∆yopD strains showed that only the wt
strain elicited the production of PO4-Elk while the ∆yopD
strain had no production of PO4-Elk. The wt and the
∆yopD strains were used to infect HeLa cells in the pres-
ence of a 1:10 or a 1:25 dilution of anti-YscF (titer for HT-
YscF, 1:100,000) or in the presence of anti-PcrG (a Yersinia
non-reactive antibody control, titer for PcrG, 1:20,000).
The wt strain was capable of translocating YopE-Elk in
presence of both anti-sera, demonstrating that anti-YscF
was not capable of blocking Yops translocation and
expectedly the ∆yopD strain was still defective for
translocation. The experiment likely contained sufficient
antibody against YscF to block translocation. In a previous
report Pettersson et al used as low as a 1:100 dilution of
an anti-LcrV anti-sera with a titer of 1:20,000 for LcrV and
in that experiment translocation of Yops into HeLa cells
was blocked [26]. These results suggest that antibody to
YscF may not exert its protective effect by blocking Yops
translocation. The results also suggest that while YscF is
surface-exposed in the yersinae, antibody directed against
YscF, unlike, anti-LcrV cannot block translocation. This
may imply that YscF activity is shielded from neutraliza-
tion by antibody, unlike LcrV activity that is blocked by
antibody in some cases. However, since anti-LcrV was
unable to block Yops translocation into by Y. pestis into
HeLa cells [21] but could block translocation into cul-
tured macrophages [41,42], the possibility remains that
anti-YscF also display this type of differential blockage.
Conclusion
In this study we have determined that immunization of
mice with recombinant YscF can protect mice from an i.v.
challenge with Y. pestis. This is the first report to our
knowledge that has utilized a conserved protein from the
type III secretion complex of a gram-negative pathogen as
a candidate for vaccine development. This result suggests
that type III secretion complexes of other gram negative
pathogens could also serve as vaccine targets. YscF and its
homologs are obvious targets for use as vaccine candi-
dates as they are surface exposed and are required for vir-
ulence in all the systems examined. The protective
antibody response elicited by HT-YscF is evidence that
YscF is not only expressed during the course of a plague
infection, but is also in a location accessible to antibodies
at some point in the infectious process. The mechanism of
protection by the YscF antibody response is currently
under investigation. Essentially three possibilities exist to
explain the antibody's protective activity: increased
opsonization of the bacteria, enhanced complement
binding to the bacterial surface, or direct blocking of Yops
translocation into the host cells. Cytotoxicity assays (data
not shown) and the ability to translocate Elk-tagged YopE
into HeLa cells (Figure 3) have shown that it is unlikely
that anti-YscF directly blocks Yops translocation into
HeLa cells. Suggesting that a blockage of Yops transloca-
tion may not be the mechanism whereby anti-YscF
antibodies are protective. The degree of protection
observed after immunization with YscF is not as great as
that seen for the two known protective antigens, F1 and
LcrV. This result suggests that YscF could be best used in
combination with the other known antigens to formulate
a tri-valent vaccine for Y. pestis. However, further work
could lead to the development of YscF as a monovalent
vaccine or combined with other antigens that could be
efficacious not only against Y. pestis, but also against Y.
enterocolitica and Y. pseudotuberculosis.
Methods
Cloning of yscF for overexpression and HT-YscF 
purification
Plasmid pJM119 was constructed by cloning a BamHI-and
XhoI-cleaved PCR product into pET24b (Novagen, Madi-
son, WI). The primers used to amplify yscF were HT-YscF
Start (5' CGG GAT CCG ATG AGT AAC TTC TCT GGA TTT
3') and HT-YscF Stop (5' CCG CTC GAG TGG GAA CTT
CTG TAG GAT GCC 3'). E. coli BL21(DE3) (Novagen) har-
boring pJM119 was used for HT-YscF overpexpressionPage 6 of 10
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purified using Talon resin (BD Clontech, Palo Alto, CA)
according the manufacturer's directions.
Immunization of mice and infection with Y. pestis KIM5
For primary immunization 6-to 8-week-old female Swiss-
Webster mice were immunized i.p. with 40 µg/mouse His-
tagged YscF or phosphate-buffered saline [37] PBS (con-
trol mice) emulsified 1:1 with complete Freund's adjuvant
(CFA). Booster immunizations were performed the same
as the primary immunization with the substitution of
Incomplete Freund's Adjuvant for CFA. Mice were chal-
lenged with Y. pestis via the retro-orbital sinus using blunt-
feeding needles. Y. pestis used to infect mice was grown
overnight in HIB broth, sub-cultured to an A620 of 0.2
absorbance units and grown with shaking to an A620 of 1.0
absorbance unit. Y. pestis cells for infection were harvested
by centrifugation and resuspended in PBS. Plate counts
were performed to verify CFUs for the infectious doses.
Infected animals were monitored for death for up to 19
days, after which survivors were euthanized by CO2 inha-
lation, according to the guidelines of the Panel on Eutha-
nasia of the American Veterinary Medical Association. All
animal work for this project was reviewed and approved
by UND's IACUC.
Bacterial strains, growth and fractionation
Bacterial strains used were KIM8-3002 [24], ∆yscF an iso-
genic in-frame deletion of yscF (G. Plano, University of
Miami), and KIM8.3002.2 ∆yopD [45]. Y. pestis strains
were grown in heart infusion broth or on tryptose blood
agar base medium (Difco Laboratories, Detroit, MI) at
26°C for genetic manipulations. For physiological stud-
ies, growth of Y. pestis was conducted in a defined
medium, TMH, as previously described [46]. Bacterial
cells were fractionated as previously described [24].
Briefly, bacterial cells were chilled on ice after growth, har-
vested by centrifugation, and washed in cold phosphate-
buffered saline (PBS; [37]). Bacterial whole cell fractions
were prepared by resuspending the washed cells in cold
PBS and precipitating total proteins with 10% (vol/vol)
trichloroacetic acid (TCA) on ice overnight. Secreted pro-
teins were recovered from the bacterial growth medium
by centrifuging the spent medium a second time, transfer-
ring the supernatant to a clean tube, and precipitating
with 10% (vol/vol) TCA on ice overnight. The TCA-pre-
Y. pestis strain KIM8-3002 (wt) (lane 1 and lanes 3–6) and KIM8-3002.2 (∆yopD) (lane 2 and lanes 7–10) both containing plasmid pYopE129-Elk were used to infect HeL  cells at an MOI of 10. 4 h following infection the culture supernatant containing non-adh rent b cteria were removed th  remaining adherent HeLa cells were solubil z d in 2X SDS-PAGE bufferFigu 3
Y. pestis strain KIM8-3002 (wt) (lane 1 and lanes 3–6) and KIM8-3002.2 (∆yopD) (lane 2 and lanes 7–10) both containing plasmid 
pYopE129-Elk were used to infect HeLa cells at an MOI of 10. 4 h following infection the culture supernatant containing non-
adherent bacteria were removed the remaining adherent HeLa cells were solubilized in 2X SDS-PAGE buffer. Following solubi-
lization proteins were separated and immunoblotted to triplicate PVDF membranes. The triplicate blots were probed with α-
YopE, α-Elk, or α-PO4-Elk, followed by incubation with an alkaline phosphatase conjugated secondary antibody and developed 
using NBT/BCIP. To some samples anti-sera specific for HT-YscF (lanes 3–4 and lanes 7–8) or the Pseudomonas protein, PcrG 
(lanes 5–6 and lanes 9–10), were added at dilutions of 1:10 (lanes 3, 5, 7, and 9) or 1:25 (lanes 4, 6, 8, and 10).Page 7 of 10
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× g at 4°C) for 20 min and resuspended in 2X sodium
dodecyl sulfate (SDS) sample buffer [37].
Protein electrophoresis, visualization and 
immunodetection
Proteins were separated by SDS-polyacrylamide gel elec-
trophoresis (SDS-PAGE), using 12.5 % or 15 % (wt/vol)
polyacrylamide gels according to the method of Laemmli
[47]. Samples were boiled 3–5 min before loading on the
gels. Samples were loaded such that lanes containing dif-
ferent culture fractions represented equivalent amounts of
the original cultures. Proteins were visualized in gels using
GelCode Blue stain (Pierce Chemical, Rockford, IL)
according to directions. For immunoblots, proteins
resolved by SDS-PAGE were transferred to Immobilon-P
membranes (Millipore Corp., Bedford, MA) using carbon-
ate transfer buffer (pH 9.9) [48]. Specific proteins were
visualized using mouse or rabbit polyclonal antibodies
specific for YopE (rabbit α-YopE; gift from G. Plano, Uni-
versity of Miami, Miami, FL), YscF (mouse α-YscF, this
study), Elk (rabbit α-Elk, Cell Signaling Technology, Bev-
erley, MA) and PO4-Elk (rabbit α-PO4-Elk, Cell Signaling
Technology). Hexahistidine tagged YscF was visualized
using a penta-histidine specific antibody (mouse α-Penta-
His, Qiagen, Valencia, CA) Alkaline phosphatase-conju-
gated secondary antibody (goat anti-rabbit immunoglob-
ulin G or goat anti-mouse immunoglobulin G; Pierce)
was used to visualize proteins by development with
nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl-
phosphate (NBT-BCIP; Fisher Scientific, Fair Lawn, NJ).
Antibody characterization and isotyping
Flat-bottom, 96-well Nunc Maxisorp immunoplates
(Fisher Scientific, Pittsburgh, PA) were coated with 100 µl
of HT-YscF solution (4 µg/ml in Binding solution (0.1 M
NaH2PO4, ph 9.0) at room temperature for 2 h (or over-
night at 4°C). The wells were blocked with 200 µl/well
blocking buffer (1% bovine serum albumin in TTBS (tris-
buffered saline [37] + 0.5% Tween 20) and washed with
TTBS. Test sera were serially diluted in blocking buffer and
100 µl of each dilution was added to duplicate wells that
were incubated for 2 h at RT (or overnight at 4°C). The
plates were washed and incubated for 2 h at RT with alka-
line-phosphatase-conjugated anti-mouse secondary anti-
body. For quantitation of YscF-specific immunoglobulin
isotypes and subclasses the plates were coated with alka-
line-phosphatase-labeled anti-mouse isotype-specific
antibody (1:400 in blocking buffer; Southern Biotech, Bir-
mingham, AL). The wells were washed and 75 µl 3 mM
para-nitro phenyl phosphate (p-NPP) was added to each
well. The plates were incubated for 15 min at RT and the
reaction was stopped by the addition of 50 µl of 1.5 M
NaOH to each well. A405 was measured to monitor the
cleavage of p-NPP. Antibody titers were determined as
reciprocal numbers of the highest serum dilution that dis-
played values for optical density twofold higher than the
value of the control serum.
Infection assays
Infection of eukaryotic cells was performed as described
previously [24]. Prior to infection, eukaryotic cells were
subcultured into 35-mm-diameter six-well tissue culture
plates in RPMI-FBS and incubated at 37°C under 5% CO2
for 48 to 72 h to a density of 5 × 105 to 8 × 105 cells per
well. Cells were washed twice with warm L15 lacking FBS
immediately prior to infection. Bacteria were cultivated at
26°C in HIB and used at an OD620 of ~1.0 for tissue
culture infections. Bacteria were added (at a multiplicity
of infection (MOI) of 5 to 10) directly to prewarmed
medium in the wells of the six-well plates. Plates were
then centrifuged at 200 × g at RT for 5 min to achieve con-
tact between the bacteria and the target cells and incu-
bated at 37°C for 4 h.
Translocation of YopE
Detection of Elk-tagged YopE from pYopE129-Elk was per-
formed as described [43]. Y. pestis strains carrying plasmid
pYopE129-Elk were used to infect HeLa cells. After 4 h, the
culture supernatants were removed, and the infected
adherent cells were lysed by the addition of 100 µl of 2X
SDS-PAGE lysis buffer containing Pefabloc (Roche Molec-
ular Biochemicals, Indianapoli, IN) and phosphatase
inhibitor (P-2850) cocktail (Sigma, St. Louis, MO). Sam-
ples were boiled for 5 min and loaded onto 12.5 % SDS-
PAGE gels, immunoblotted to PVDF membranes and
probed with Elk-1 (#9182) or phosphospecific Elk-1
(#9181) antibody preparations (Cell Signaling Technol-
ogy). Anti-sera specific for HT-YscF (titer of 1:100,000,
this study) or the Pseudomonas aeruginosa LcrG homolog,
PcrG (titer of 1:20,000, Matson and Nilles, unpublished),
were used at dilutions of 1:10 or 1:25 in the infection
medium to assess the ability of α-YscF to effect YopE
translocation.
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